Acumen Research and Consulting, Recently Published Report titled “Irritable Bowel Syndrome Treatment Market Size, Share, Trends, Growth and Forecast 2019-2026”.
LOS ANGELES, July 16, 2019 (GLOBE NEWSWIRE) -- The global irritable bowel syndrome treatment market size is estimated to grow at CAGR above 9.8 % over the forecast time frame and reach the market value around US$ 3.4 billion by 2026.
The growing incidence of target diseases and the expansion of current medicines labels are expected to accelerate market growth. Furthermore, increasing use of medicines and the launch of new goods are expected to drive the market for IBS (Irritable Bowel Syndrome).
Free Download Sample Report Pages for Better understanding@ https://www.acumenresearchandconsulting.com/request-sample/1528
IBS is one of the most popular gastrointestinal illnesses with a incidence of 10-15% globally. Most IBS individuals are under the age of 50 but many elderly people also suffer. The impact of this disease may range from mild discomfort to severe weakness. It can regulate several aspects of the professional, emotional and social lives of a patient. Moderate to serious patients typically have symptoms which often adversely affect their mental, physical, educational, social, and financial well-being.
Symptoms may differ, and constipation may alternate with diarrhea, sometimes contradictory. These variables add to the need for irritable bowel syndrome treatments which allow patients to continue with their daily lives. The syndrome of long term patients is likely to disrupt their private and professional operations, and normally limits their potential.
Roughly 40% of patients suffer from mild IBS, 35% have moderate IBS, and 25% have serious IBS. Many individuals are unable to differentiate between IBS symptoms; it is still one of the most frequent illnesses that doctors are diagnosed. Not all people with IBS symptoms have the same therapy. However, approximately 2.4 to 3.5 million doctor calls are given annually in the United States alone for irritable bowel syndrome. It impacts approximately 35–40% of men and 60%–65% of women worldwide.
View Detail Information with Complete TOC@ https://www.acumenresearchandconsulting.com/irritable-bowel-syndrome-treatment-market
Key Highlights
Due to the increasing incidence and increasing intake of medication such as Linzess / Constella and Amitiza, IBS-C was the biggest producing income segment per form in 2018.
Due to increased product acceptance in significant areas like the U.S., Germany, U.K., Italy, Spain, and Japan, Linzess / Constella was in 2018 the market leader on the worldwide IBS therapy market.
The biggest income-generating region in 2018, North America was projected to be, followed by Europe. The main contributors are the presence of important players in the industry, the elevated level of attention to patients, the powerful presence of new products and the established health infrastructure.
Over the forecast period, Europe is expected to be the fastest developing region. Increased marketing and the existence of a big target population drive the IBS therapy market.
Players have adopted policies to boost their market share, such as extension of products, product growth, regional expansion, and fusions and acquisitions. In April 2015, the company purchased a portfolio focused on gastrointestinal medicines by Salix Pharmaceuticalals.
Browse all official Market Research Reports Press Releases@ https://www.acumenresearchandconsulting.com/press-releases
Explore Our Market Blog@ https://www.acumenresearchandconsulting.com/blogs
Irritable bowel syndrome is a gastrointestinal functional intestinal disorder which may be defined by contractions of the colon muscle. The big intestine is affected by irritable bowel syndrome. Irritable bowel syndrome is caused by bowel dysfunction and is mostly present in the elderly.
Key Players & Strategies
Some of the key players in the market are Allergan; Ironwood Pharmaceuticals, Inc.; Synergy Pharmaceuticals Inc., Bausch Health; Takeda Pharmaceutical Company Limited AstraZeneca; Sebela Pharmaceuticals Inc.; Synthetic Biologics, Inc.; Astellas Pharma, Inc.; and Ardelyx. The main players have adopted distinct approaches for increasing their market share, such as mergers and acquisitions. In April 2015, for example, Bausch Health purchased a portfolio of Salix Pharmaceuticals focusing on gastrointestinal medicine.
In order to expands its market presence, players are also focused on launching their products in distinct areas. Ironwood Pharmaceuticals and AstraZeneca obtained marketing permission for Linzess in China in January 2019, for example, to enhance their market position.
Acumen Research and Consulting Enters Partnership with MARKETWATCH, Click Here
Request for Customization@ https://www.acumenresearchandconsulting.com/request-customization/1528
The report is readily available and can be dispatched immediately after payment confirmation.
Buy this premium research report - https://www.acumenresearchandconsulting.com/buy-now/0/1528
If you would like to place an order or have any questions, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157
For Latest Update Follow Us:
https://www.facebook.com/acumenresearchandconsulting
https://www.linkedin.com/company/acumen-research-and-consulting/